Pay in 4 interest-free payments of $5.20 Learn more
Ships within 48 hours · Estimated delivery Aug 29 - Sep 3
Phase 1a: First-in-Human Single Ascending Dose Study (NCT02951806) Study Title: "Safety, Tolerability, and Pharmacokinetics of Single Doses of Cagrilintide in Healthy Subjects" Status: Completed Phase: Phase 1a Enrollment: 48 healthy volunteers Study Period: 2016-2017 Location: Single center (Denmark) Design: Randomized, double-blind, placebo-controlled, single ascending dose Dose Range: 0.03-10 mg SC Primary Endpoints: Safety, tolerability, PK parameters Population: Healthy male subjects, BMI 20-28 Key Results: Pharmacokinetics: Terminal half-life 5-7 days across dose range
How do you balance efficacy and metabolic safety when prescribing longterm Olanzapine
Created using the Company's proprietary LENS ai platform, an AI-driven system that analyzes evolutionary patterns in biological data, these novel AI-generated sequences have been optimized to maximize therapeutic performance while improving the patient experience
IV Therapy & Gut Support Nutrient deficiencies and gut dysfunction play a major role in metabolic health
Keep reading to see how it worksand why patients at Majestic Aesthetics are calling it a game-changer
Chase Lay and our fantastic team
US$ 26.09
US$ 24.43
US$ 22.11
